Zhang Jianfu, Shao Shurong, Ye Chaohui, Jiang Bengui
Department of Pharmacy, Ningbo Women and Children's Hospital, Ningbo 315012, China.
Department of Gynecology, Ningbo Women and Children's Hospital, Ningbo 315012, China.
Evid Based Complement Alternat Med. 2021 Oct 16;2021:8037459. doi: 10.1155/2021/8037459. eCollection 2021.
In this prospective study, we randomly divided 100 patients with perimenopausal syndrome equally into the control group ( = 50) receiving conventional treatment and the study group ( = 50) receiving estradiol valerate. The indicators observed were endometrial thickness, uterine volume, and the levels of LH (luteinizing hormone), FSH (follicle-stimulating hormone), and E2 (estradiol) of the patients before and after treatment. The Pittsburgh Sleep Quality Index (PSQI), Hamilton Anxiety/Depression Scale (HAMA/HAMD), Kupperman symptom score, and menopause-specific quality of life (MENQOL) were also applied to assess the sleep quality, negative emotions, severity of the condition, and quality of life of all patients, respectively. Our findings were that estradiol valerate is beneficial in improving serum sex hormone levels, sleep disturbances, negative mood, and quality of life in patients with perimenopausal syndrome and that its safety profile is high enough to warrant clinical promotion.
在这项前瞻性研究中，我们将100例围绝经期综合征患者随机均分为对照组（n = 50）和研究组（n = 50），对照组接受常规治疗，研究组接受戊酸雌二醇治疗。观察指标为患者治疗前后的子宫内膜厚度、子宫体积以及促黄体生成素（LH）、促卵泡生成素（FSH）和雌二醇（E2）水平。还应用匹兹堡睡眠质量指数（PSQI）、汉密尔顿焦虑/抑郁量表（HAMA/HAMD）、库珀曼症状评分和绝经特异性生活质量量表（MENQOL）分别评估所有患者的睡眠质量、负面情绪、病情严重程度和生活质量。我们的研究结果表明，戊酸雌二醇有助于改善围绝经期综合征患者的血清性激素水平、睡眠障碍、负面情绪和生活质量，并且其安全性足以支持临床推广。
